Clinical trials: HLA Antigens
Hematologic Malignancies, Hematologic Neoplasms
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone.
- Trial name
- NCT07162038
- Testing
- mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- National Cancer Institute (NCI)
Living Donor Kidney Transplantation
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along…
- Trial name
- NCT03943238
- Testing
- Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Lymphoma, Myeloma
Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions
The purpose of this research study is to examine the safety of infusing escalated doses of allogeneic (from a relative of the patient), enriched natural killer (NK) cells after autologous (from the patient) stem cell…
- Conditions
- Lymphoma, Myeloma, Leukemia
- Trial name
- NCT00660166
- Testing
- NK-Cell Infusion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Tufts Medical Center
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Healthy, Transfusion Reactions
Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients
This study will determine if transfusion of platelets containing HLA antibodies (certain antibodies to white blood cells) are more likely to cause transfusion reactions than transfusion of platelets that do not contain HLA…
- Trial name
- NCT00460122
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Astrocytoma, Oligoastrocytoma
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
This is a pilot vaccine study in adults with recurrent WHO Grade II gliomas. The purpose of this study is to test the safety and efficacy of an experimental tumor vaccine made from peptides in combination with the study drug…
- Conditions
- Astrocytoma, Oligoastrocytoma, Oligodendroglioma
- Trial name
- NCT00874861
- Testing
- Peptide vaccine + Poly-ICLC
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ian F. Pollack, M.D.
Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4)…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Adult, Acute Myeloid Leukemia Refractory, Chronic Myeloid Leukemia - Accelerated Phase, Myelodysplastic Syndromes
- Trial name
- BMT-13 (NCT06802315)
- Testing
- Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Illinois Chicago
Renal Failure , Chronic, Graft Failure
Study to Compare the Outcome of Receiving Continued Immunosuppression Versus Stopping Immunosuppression at 6 Months to Safely Prevent Human Leukocyte Antigen (HLA) Sensitization in Patients With Late Renal Graft Failure
The goal of this clinical trial is to compare the degree of HLA sensitization at 2 years in patients with late renal graft failure (> 3 months) when receiving reduced immunosuppressant treatment versus stopping immunosuppression…
- Conditions
- Renal Failure , Chronic, Graft Failure, Graft Rejection, Allograft
- Trial name
- NCT06676696
- Testing
- Continue low dose calcineurin inhibitor (CNI), Calcineurin inhibitor withdrawal at 6 months
- Where
- Spain
- Volunteers
- 202 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Colorectal Cancer, Colon Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Colorectal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides RNF43, TOMM34, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51 in combination with Tegafur/Uracil/Folinate…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT00677287
- Testing
- RNF43, TOMM34, VEGFR1 and VEGFR2
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Hematologic Malignancies
A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies
This is an open-label, prospective, observational, multicenter, randomized study to compare the efficacy between unrelated umbilical cord blood transplantation (UCBT) and HLA-haploidentical related hematopoietic stem cell…
- Trial name
- NCT02386332
- Testing
- transplantation
- Volunteers
- 206 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
End Stage Renal Disease
Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients
The purpose of this study is to demonstrate the safety of tacrolimus extended-release in HLA sensitized (HS, defined as panel reactive antibody ≥ 30%), kidney transplant recipients after desensitization with intravenous…
- Trial name
- NCT03194321
- Testing
- Tacrolimus Extended-Release Oral Capsule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Breast Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptide TTK emulsified with Montanide ISA 51.
- Trial name
- NCT00678509
- Testing
- TTK peptide mixed with Montanide ISA 51
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Melanoma, Neoplasm Metastasis
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
This is a study of a melanoma tumor antigen peptide vaccine. Peptides representing HLA-A201 restricted T cell epitopes of the melanoma antigens, MART-1, gp100 and tyrosinase will be administered emulsified in Incomplete Freund's…
- Trial name
- NCT00001685
- Testing
- Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- National Cancer Institute (NCI)
Myeloid Malignancies
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated…
- Trial name
- GITMO-PHYLOS (NCT03270748)
- Testing
- GvHD prophylaxis
- Where
- 33 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Organ Transplantation
Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Transplantation is the only treatment for end-stage organ dysfunction, with dialysis for the kidney. However, donor / recipient (D / R) tissue incompatibility accounts for the majority of long-term graft losses, through the…
- Trial name
- ACORG-HLA (NCT03861962)
- Testing
- DNA sequencing called "new generation" (or NGS)
- Volunteers
- 20,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris